LACTOLOGY FOUNDATION

Synthetic anticholinergic agents in combination with psycholeptics (ATC A03CA) are rarely used, primarily older combination products where a peripheral antimuscarinic is added to sedative or anxiolytic psycholeptics for functional gastrointestinal disorders; their use during breastfeeding is generally discouraged due to anticholinergic and sedative effects on the infant and potential impact on lactation, so safer alternatives should be preferred whenever possible.medpedia.framar+5

Pharmacological class and representatives

ATC group A03CA belongs to “Drugs for functional gastrointestinal disorders” within the alimentary tract and metabolism group.wikipedia+1
It comprises synthetic anticholinergic (antimuscarinic) agents such as isopropamide, clidinium, oxyphencyclimine, otilonium bromide, glycopyrronium, bevonium, ambutonium, diphemanil, emepronium and propantheline, each combined with psycholeptics (mainly sedative/anxiolytic or antipsychotic agents).atcddd.fhi+4

Mechanism of action

The anticholinergic component acts as a competitive antagonist at muscarinic acetylcholine receptors in the enteric nervous system, reducing parasympathetic tone, intestinal smooth muscle spasm and secretions.pmc.ncbi.nlm.nih+1
Psycholeptics in these combinations (e.g. phenothiazines, benzodiazepines or other sedative agents) provide additional anxiolytic, antiemetic and central sedative effects, which may modulate visceral perception but also add CNS depression and other psychotropic adverse effects.truemeds+4

Therapeutic indications

Historically, A03CA combinations were indicated for functional gastrointestinal disorders such as irritable bowel–type complaints, painful intestinal spasms, dyspepsia and adjunctive treatment of peptic disease with a strong anxiety component.naver+2
They are now largely superseded by more specific and better-tolerated agents (e.g. selective antispasmodics, proton pump inhibitors, modern anxiolytics), so current use is limited and many products are unavailable in numerous markets.atcddd.fhi+3

General toxicological profile

These drugs share the typical antimuscarinic toxicity profile: dose-related dry mouth, decreased sweating, tachycardia, blurred vision, mydriasis, urinary retention, constipation and potential hyperthermia, especially in vulnerable patients.1mg+2
Central effects may include agitation, confusion, hallucinations, memory impairment and delirium, particularly in children, the elderly and in overdose, and are amplified when psycholeptics with sedative or antipsychotic properties are co-administered.medpedia.framar+3

Overdose and poisoning

Acute intoxication with A03CA combinations typically presents with an “anticholinergic syndrome”: hot, dry skin, hyperthermia, tachycardia, dilated non-reactive pupils, decreased bowel sounds, urinary retention, agitation and delirium, often followed by somnolence or coma from the psycholeptic component.pmc.ncbi.nlm.nih+2
Cardiac conduction disturbances, seizures, severe hypotension or respiratory depression may occur depending on the specific psycholeptic (e.g. phenothiazines), and polypharmacy in psychiatric patients increases the risk of complex drug–drug interactions.pubmed.ncbi.nlm.nih+4

Drug–drug interactions

Pharmacodynamic interactions are frequent: co-administration with other anticholinergics (e.g. tricyclic antidepressants, antiparkinson drugs) or sedatives enhances anticholinergic burden and CNS depression.rrpharmacology+1
Pharmacokinetic interactions have been documented, such as trihexyphenidyl increasing plasma chlorpromazine levels by about 40%, illustrating that anticholinergics can alter psycholeptic disposition, though this specific pair is not strictly A03CA but mechanistically comparable.pubmed.ncbi.nlm.nih+2

Safety in pregnancy

Given their age and limited contemporary use, controlled human data in pregnancy are scarce, and many A03CA products are absent from modern obstetric practice.naver+2
By extrapolation from related antimuscarinics and sedative psycholeptics, potential risks include maternal hypotension, reduced uterine perfusion, neonatal CNS and respiratory depression and anticholinergic effects, so they should generally be avoided in pregnancy unless no safer alternative exists and expected benefit clearly outweighs potential harm.lllusa+2

Lactation: transfer into milk

Physicochemical properties of typical A03CA anticholinergics (quaternary ammonium or polar tertiary amines) suggest limited oral bioavailability and relatively poor penetration into breast milk, while many psycholeptics are lipophilic and achieve measurable milk levels.1mg+3
Due to sparse direct data and the overall low contemporary use of these exact combinations, most lactation-focused resources emphasize individualized assessment and favor drugs with better-characterized lactation safety profiles instead of legacy fixed-dose anticholinergic–psycholeptic combinations.e-lactation+2

Lactation: effects on the breastfed infant

Potential infant effects include sedation, hypotonia, feeding difficulties, constipation, urinary retention and, in high exposure, anticholinergic manifestations such as irritability, fever and poor weight gain.lllusa+3
Infants, especially neonates and preterm babies, have immature metabolism and reduced capacity to clear both anticholinergics and psycholeptics, so adverse CNS and cardiorespiratory events may occur at lower relative doses than in adults, prompting a cautious or avoidant approach.infantrisk+3

Lactation: impact on milk production

Anticholinergic agents may theoretically decrease milk production by inhibiting parasympathetic-mediated prolactin release and reflex milk ejection, although robust clinical data for A03CA molecules are lacking.e-lactation+2
Sedative psycholeptics can further impair breastfeeding through maternal somnolence, reduced responsiveness to infant cues and decreased frequency of feeds, which secondarily reduces milk supply.infantrisk+3

Clinical recommendations for breastfeeding

For functional gastrointestinal complaints in breastfeeding mothers, non-pharmacological interventions and better-studied alternatives (e.g. pure antispasmodics without CNS-active psycholeptics, PPIs or H2 blockers when appropriate) are preferred over A03CA combinations.medpedia.framar+4
If an A03CA combination is considered indispensable, it should be prescribed at the lowest effective dose, for the shortest possible duration, with close monitoring of the infant for sedation, feeding problems, poor weight gain, constipation and signs of anticholinergic toxicity, and breastfeeding should be reconsidered if clinically significant symptoms appear.pmc.ncbi.nlm.nih+4

Contraindications and high-risk situations

Use is generally contraindicated or strongly discouraged in mothers and infants with glaucoma, urinary retention, significant prostatic hypertrophy, severe constipation, ileus, myasthenia gravis, severe cardiovascular disease or pre-existing CNS depression.1mg+2
Breastfeeding should be avoided or alternative therapy chosen in premature infants, those with cardiorespiratory instability, neurological disease or history of apnoea, where even modest anticholinergic and sedative exposure can destabilize clinical status.lllusa+3

Practical counseling points

Healthcare professionals should document the exact product, dose, duration and gestational/postnatal age when assessing risk, and consult specialized lactation pharmacology resources to evaluate case-specific safety.e-lactation+2
Counsel mothers on recognizing infant warning signs (excessive sleepiness, poor suck, reduced wet diapers, fever, breathing irregularities) and on promptly seeking medical care if these occur, while also reassessing the necessity of continuing the A03CA combination.infantrisk+3